LDL-apheresis in acute anterior ischemic optic neuropathy.
Acute anterior ischemic optic neuropathy (AION) is a disabling disease which impairs visual function. Standard treatment is unable to affect the outcome and the visual damage persists. We describe the case of a 64-year-old patient affected by AION, whose only known risk factor was hypercholesterolemia. After a first onset of involvement of the right eye (RE), the patient presented four weeks later with an analogous episode affecting the left eye (LE). Since standard treatment, started at involvement of the RE, had not yielded any beneficial effect, the patient underwent three sessions of LDL apheresis. The scotomatous portion of the visual field reduced even after the first session, there was further improvement after the third, and after six months the condition remained stable. Corrected vision improved from 2/10 to 6/10 after the third session. LDL cholesterol and fibrinogen decresade after the third session from 239 mg/dL to 31 mg/dL and from 289 mg/dL to 92 mg/dL, respectively. In conclusion, thanks to its effect of antagonizing hemorheologic disorders of the ocular microcirculation, LDL apheresis seems to be an efficacious treatment of AION, especially in patients suffering from hypercholesterolemia.
Ramunni
A
A
Division of Nephrology, Department of Internal and Public Medicine, University of Bari, Bari, Italy. a.ramunni@nephro.uniba.it
Giancipoli
G
G
Saracino
A
A
Guerriero
S
S
Saliani
M T
MT
Gentile
M C
MC
Sborgia
C
C
Coratelli
P
P
D001781:Blood Component Removal / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008875:Middle Aged; D018917:Optic Neuropathy, Ischemic / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014792:Visual Acuity
D008077:Lipoproteins, LDL